| | Features | Idiopathic autoimmune uveitis (N = 16) | Anterior uveitis (N = 11) | Panuveitis (N = 4) | Posterior uveitis (N = 1) |
| | Age in years, median (IQR) | 41 (37–58.2) | 41 (40–60) | 41 (23.8–65) | 37 | | Female, n (%) | 10 (62.5) | 6 (54.5) | 4 (100) | — | | Uveitis duration in month, median (IQR) | 24 (6.3–36) | 12 (6–36) | 30 (11.3–126) | 36 |
| | Past treatment history | | Treatment refractory, n’ (n) | 4 (13) | 2 (8) | 2 (4) | 1 | | Treatment naïve, n’ (n) | 5 (13) | 3 (8) | 1 (4) | — | | Treatment responsive, n’ (n) | 4 (13) | 3 (8) | 1 (4) | — |
| | Tuberculin sensitivity test, n’ (n) | | Interferon gamma release assay, n’ (n) | 3 (12) | 2 (7) | 1 (3) | 0 (1) | | CXR PA view for TB, n’ (n) | 0 (7) | 0 (3) | 0 (1) | 0 (1) | | Sacroiliac MRI, n’ (n) | 0 (12) | 0 (9) | 0 (2) | 0 (1) | | ANA (IFA), n’ (n) | 0 (6) | 0 (5) | — | 0 (1) | | AntiPR3/MPO, n’ (n) | 2 (5) | 1 (3) | 1 (1) | — | | ACE, n’ (n) | 0 (5) | 0 (3) | 0 (1) | 0 (1) | | CRP, median (IQR) | 0 (12) | 0 (7) | 0 (4) | 0 (1) | | ESR, median (IQR) | 5.1 (2–8) | 5.1 (2.4–8) | 7.4 (2–32) | 1.1 | | Topical treatment | 16 (10–40) | 18 (10–40) | 16 (15–57) | 6 | | Topical steroid, n (%) | 15 (93.8) | 11 (100) | 4 (100) | — | | Topical cycloplegics/mydriatics, n (%) | 12 (75) | 9 (75) | 3 (75) | — |
| | Regional therapy | | Intraocular steroid, n (%) | 1 (6.3) | — | 1 (25) | — | | Systemic steroids n (%) | 9 (56.3) | 4 (36.4) | 3 (75) | — | | Intravenous steroid, n (%) | 4 (25) | 2 (18.2) | 1 (25) | — | | Oral steroid, n (%) | 8 (50) | 3 (27.3) | 3 (75) | 11 |
| | Additional immunosuppression | | Steroid sparing, n (%) | 7 (43.8) | 5 (45.5) | 2 (50) | 1 | | Mycophenolate mofetil, n (%) | 2 (12.5) | — | 2 (50) | 1 | | Methotrexate, n (%) | 4 (25) | 3 (27.3) | 1 (25) | — | | Sulfasalazine, n (%) | 3 (18.8) | 3 (27.3) | — | — | | Other therapy, n (%) | 1 (6.3) | — | 1 (25) | — | | 2nd DMARD, n (%) | 3 (18.8) | 2 (18.2) | 1 (25) | — |
|
|
